BNT162b2 not checked

BioNTech

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
3 active
28 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will receive a single injection containing variant-adapted BNT162b2 on Day 1.”In the company’s words, NCT07730450 on ClinicalTrials.gov
Tested for
COVID-19 Vaccines (2 trials)
Main trialPhase 4
“The purpose of this study is to learn about the safety and effects of an updated COVID-19 vaccine (called BNT162b2) in adults 18 to 64 years of age. This study is seeking participants who: * are medically stable * have not had a recent COVID-19 infection * have not had a recent vaccination * do not have medical conditions that increase their risk of complications from COVID-19 All participants in this study will randomly receive 1 injection into their arm of either: * BNT162b2 vaccine which targets COVID-19 and is selected for the 2026-2027 COVID-19 season, or * Tdap vaccine which targets…”In the company’s words, NCT07730450 on ClinicalTrials.gov
Other names
Comirnaty

Other drugs for COVID-19 Vaccines

All 43 drugs for COVID-19 Vaccines

Coming up2

Changes2

Last 90 days

Trials28

TrialPhaseCompletesWhat it tests
Phase 4Recruiting 20 Aug 2027 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age
Phase 3Active, not recruiting 12 Apr 2027 A Study of COVID-19 Vaccine(s) in Children and Adults
Phase 4Completed 25 Nov 2021 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults
Phase 3Completed 22 Jul 2021 A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 RNA-Based COVID-19 Vaccines Against COVID-19 in Healthy Participants
Phase 3Completed 1 Dec 2021 A Study to Evaluate Safety, Tolerability, & Immunogenicity of Multiple Formulations of BNT162b2 Against COVID-19 in Healthy Adults
Phase 3Completed 5 Oct 2022 Safety and Immunogenicity of BNT162b2 Coadministered With SIIV in Adults 18 Through 64 Years of Age
Phase 3Completed 25 May 2023 To Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of BNT162b2 Boosting Strategies Against COVID-19 in Participants ≥12 Years of Age.
Phase 3Completed 4 Oct 2023 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children
Phase 3Completed 1 May 2026 A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
Phase 3Completed 10 Jul 2026 A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Phase 3Completed 24 Jul 2026 A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19
Phase 3Completed 22 Sep 2026 A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
Phase 2/3Completed 15 Jul 2022 To Evaluate the Safety, Tolerability, and Immunogenicity of BNT162b2 Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older
Phase 2/3Completed 10 Feb 2023 Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals
Phase 2/3Completed 26 Mar 2024 A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals
Phase 2/3Completed 13 Mar 2025 A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
Phase 2Completed 7 Feb 2021 Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population
Phase 2Completed 14 Apr 2022 A Trial Investigating the Safety and Effects of One or Two Additional Doses of Comirnaty or One Dose of BNT162b2s01 in BNT162-01 or BNT162-04 Trial Subjects
Phase 2Completed 23 Jul 2023 Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
Phase 2Completed 16 Aug 2023 Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
Phase 2Completed 28 Dec 2023 A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Combined Modified RNA Vaccine Candidates Against COVID-19 and Influenza
Phase 1/2Completed 30 Jun 2021 A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 in Healthy and Immunocompromised Adults
Phase 1Completed 22 Nov 2024 Safety and Effects of an Investigational COVID-19 Vaccine as Booster in Healthy People
Phase 1Withdrawn 13 Jul 2026 A Study to Learn About Bivalent COVID-19 RNA Vaccine Candidate(s) in Healthy Infants and Children
Phase 2Ended not given Intradermal administration of a COVID-19 mRNA vaccine in elderly
Phase 4Authorised not given Temporal kinetics of antibody and cellular response markers and relative impact of revaccination in patients recovered from COVID-19 after treatment with monoclonal antibodies
Phase 2Ended not given CONCOMITANT ADMINISTRATION OF LICENSED VACCINES AGAINST COVID-19 AND FLU WITH OR WITHOUT MF59 ADJUVANT: A MULTI-CENTRE, RANDOMIZED, SINGLE-BLIND CLINICAL TRIAL TO ASSESS IMMUNOGENICITY IN ADULTS AGED 65 AND OVER
Phase 4Ended not given COVID-19 vaccine immunological studies in Finland
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow BNT162b2

Following is part of Solo: you see every change to BNT162b2 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in